000 05985cam a2200577Ii 4500
001 9781351041904
003 FlBoTFG
005 20220509193117.0
006 m o d
007 cr cnu---unuuu
008 190223s2019 si ob 001 0 eng d
040 _aOCoLC-P
_beng
_erda
_cOCoLC-P
020 _a9781351041898
_qelectronic book
020 _a1351041894
_qelectronic book
020 _a9781351041904
_qelectronic book
020 _a1351041908
_qelectronic book
020 _a9781351041874
_qelectronic book
020 _a1351041878
_qelectronic book
020 _a9781351041881
_qelectronic book
020 _a1351041886
_qelectronic book
035 _a(OCoLC)1088341308
035 _a(OCoLC-P)1088341308
050 4 _aQR46
_b.M53 2019
072 7 _aMED
_x009000
_2bisacsh
072 7 _aMED
_x022090
_2bisacsh
072 7 _aMED
_x071000
_2bisacsh
072 7 _aTCB
_2bicssc
082 0 4 _a616.99/401
_223
245 0 0 _aMicrobial infections and cancer therapy /
_cedited by Ananda M. Chakrabarty, Arsénio M. Fialho.
264 1 _aSingapore :
_bPan Stanford Publishing Pte. Ltd.,
_c[2019]
300 _a1 online resource
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
505 0 _aCover; Half Title; Title Page; Copyright Page; Table of Contents; Preface; 1: Bifidobacterium as a Delivery System of Functional Genes for Cancer Therapy; 1.1 The Potential Superiority of Bifidobacterium as a Delivery System for Cancer Gene Therapy; 1.1.1 The Biological Features of Bifidobacterium Associated with Cancer Gene Therapy; 1.1.2 Endogenous Plasmids and Cloning Vectors in Bifidobacterium; 1.1.3 Expression Plasmids in Bifidobacterium for Cancer Gene Therapy; 1.1.3.1 Plasmid pBLES100; 1.1.3.2 Plasmid pGEX-1LamdaT; 1.1.3.3 Plasmids pBV220 and pBV22210
505 8 _a1.2 The Anticancer Mechanism of Bifidobacterium as an Oral Delivery System for Cancer Gene Therapy1.2.1 Oral Administration of Bifidobacterium Affects the Immune System; 1.2.2 Oral Administration of Bifidobacterium Modulates Gut Microbial Community; 1.2.3 Oral Administration of Bifidobacterium Affects Cancer Cell Signal Transduction; 1.3 The Application of Bifidobacterium as a Delivery System of Functional Genes for Cancer Therapy; 1.3.1 Bifidobacterium as a Delivery System of Functional Genes for Cancer Gene Therapy; 1.3.2 Bifidobacterium Combination with Other Fac tors for Synergy
505 8 _a1.3.2.1 Combination with radiation and chemotherapeutic drugs1.3.2.2 Combination with prebiotics; 1.3.2.3 Combination with trace element selenium; 1.3.3 The New Mutagenesis Strategies for Genetic Modification of Bifidobacterium; 1.3.3.1 Single-crossover plasmid insertion; 1.3.3.2 Double-crossover and double-crossover markerless gene deletion; 1.3.3.3 Homologous recombination mediated by a temperature-sensitive plasmid; 1.4 Future Prospects; 2: Therapy with Oncolytic Clostridium novyi-NT: From Mice to Men; 2.1 Targeted Therapies at the Tissue Level
505 8 _a2.2 Clostridia as Live Therapeutic Agents for Cancer Therapy2.3 C. novyt NT as a Live Therapeutic Agent for Cancer Therapy; 2.3.1 C. novyi; 2.3.2 C. novyi-NT; 2.4 Preclinical Studies: Toxicity Associated with C. novyi-NT Treatment; 2.5 Preclinical Studies: Therapeutic Effects; 2.6 Preclinical Studies: Combination Approaches for Optimized Efficacy; 2.7 From Bench to Bedside; 2.8 Clinical Studies: Canine Trial; 2.9 Clinical Studies: Phase I Human Trial; 2.10 Summaiy and Future Perspectives; 3: Genetic Engineering of Clostridial Strains for Cancer Therapy
505 8 _a3.1 Tumor Hypoxia and Necrosis: A Blessing in Disguise?3.2 Clostridia as Cancer-Fighting Agents; 3.2.1 Embodiment of Treatment; 3.2.1.1 Administration route and form; 3.2.1.2 Tumor colonization; 3.2.1.3 Mechanism of action; 3.2.1.4 Termination of treatment; 3.2.2 Limitations of Clostridial Oncolysis; 3.3 Genetic Engineering Approaches; 3.3.1 The Underpinning Science; 3.3.1.1 Genetic tools; 3.3.1.2 Strain selection; 3.3.2 Clostridial-Directed Enzyme Prodrug Therapy; 3.3.2.1 Cytosine deaminase; 3.3.2.2 Nitroreductases; 3.3.2.3 Carboxypeptidase G2; 3.3.3 Clostridial-Directed Antibody Therapy
500 _a3.3.3.1 Anti-hypoxia-inducible factor 1 alpha antibody
520 _aThis book deals with the emerging concept that certain pathogenic bacteria and viruses, when infecting people with cancer, actively fight tumors, allowing their regression. Although such observations go back more than 100 years, use of specific bacterial strains, or viruses, usually genetically modified with known anticancer drugs, and their protein/peptide products, has gained ground in recent years, allowing significant cancer regression in clinical trials with stage III/IV cancer patients or even in pediatric brain tumor patients, often without any demonstration of toxicity. It is composed of 12 chapters written by pioneers in microbial, biotech, and cancer research and covers the emerging roles of various microorganisms and their products in cancer therapy. The book highlights the benefits of using conventional cancer treatments (such as chemo- and radiotherapies) with microbial-based therapies. Such combinatorial therapies have gained particular attention as a strategy to overcome drug resistance, and the readers of the book will discover their impact on fundamental research and promising results from clinical trials.
588 _aOCLC-licensed vendor bibliographic record.
650 0 _aMedical microbiology.
650 0 _aCancer
_xTreatment.
650 7 _aMEDICAL / Biotechnology
_2bisacsh
650 7 _aMEDICAL / Infectious Diseases
_2bisacsh
650 7 _aMEDICAL / Pharmacology
_2bisacsh
700 1 _aFialho, Arsenio,
_eeditor.
700 1 _aChakrabarty, Ananda M.,
_d1938-
_eeditor.
856 4 0 _3Taylor & Francis
_uhttps://www.taylorfrancis.com/books/9781351041904
856 4 2 _3OCLC metadata license agreement
_uhttp://www.oclc.org/content/dam/oclc/forms/terms/vbrl-201703.pdf
999 _c130091
_d130091